CL2025003846A1 - Formulación de vacuna que comprende un tensioactivo que no comprende un enlace éster - Google Patents

Formulación de vacuna que comprende un tensioactivo que no comprende un enlace éster

Info

Publication number
CL2025003846A1
CL2025003846A1 CL2025003846A CL2025003846A CL2025003846A1 CL 2025003846 A1 CL2025003846 A1 CL 2025003846A1 CL 2025003846 A CL2025003846 A CL 2025003846A CL 2025003846 A CL2025003846 A CL 2025003846A CL 2025003846 A1 CL2025003846 A1 CL 2025003846A1
Authority
CL
Chile
Prior art keywords
surfactant
ester linkage
vaccine formulation
formulation
vaccine
Prior art date
Application number
CL2025003846A
Other languages
English (en)
Inventor
Mombarg Erwin
Janssen Frank
KROSSØY Bjørn
Original Assignee
Vaxxinova Norway As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxxinova Norway As filed Critical Vaxxinova Norway As
Publication of CL2025003846A1 publication Critical patent/CL2025003846A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una formulación de vacuna que comprende al menos un virus o bacteria inactivado, o un fragmento inmunogénico del mismo. La formulación además comprende uno o más tensioactivos, en donde al menos un tensioactivo no comprende un enlace éster
CL2025003846A 2023-06-06 2025-12-05 Formulación de vacuna que comprende un tensioactivo que no comprende un enlace éster CL2025003846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23177589.1A EP4473960A1 (en) 2023-06-06 2023-06-06 Vaccine formulation comprising a surfactant that does not comprise an ester bond

Publications (1)

Publication Number Publication Date
CL2025003846A1 true CL2025003846A1 (es) 2026-03-06

Family

ID=86693003

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003846A CL2025003846A1 (es) 2023-06-06 2025-12-05 Formulación de vacuna que comprende un tensioactivo que no comprende un enlace éster

Country Status (3)

Country Link
EP (2) EP4473960A1 (es)
CL (1) CL2025003846A1 (es)
WO (1) WO2024251874A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277339T3 (es) * 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
CA2721800A1 (en) * 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
WO2010103022A2 (en) * 2009-03-12 2010-09-16 Sanofi Pasteur Oil-in-water adjuvanted influenza vaccine
WO2021247542A2 (en) * 2020-06-01 2021-12-09 Advent Therapeutics, Inc. Pharmaceutical compositions comprising insoluble active ingredients

Also Published As

Publication number Publication date
EP4473960A1 (en) 2024-12-11
EP4724037A1 (en) 2026-04-15
WO2024251874A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
CO2023001072A2 (es) Vacuna combinada de sars-cov-2 e influenza
MY207429A (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
NI202000039A (es) Formulaciones de composiciones de vacuna contra el vírus del dengue
NO20090897L (no) Vaksine
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
PE20211095A1 (es) Composiciones de escherichia coli y metodos de estas
AR057586A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
DOP2010000188A (es) Una vacuna de vih que comprende una proteina y un agente estabilizador
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
MX2023015327A (es) Antigenos de la influenza novedosos.
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
ZA202104747B (en) Novel trypanosomal vaccine
MX2019002248A (es) Proteina de union al factor h modificada.
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
BR112022013537A2 (pt) Composições de vacina viral e métodos de preparações das mesmas
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
NZ591188A (en) West nile virus vaccine
MX2024004252A (es) Vacunas antigripales multivalentes.
MX2024003507A (es) Mutantes del virus de la influenza b y usos de los mismos.
ZA202104746B (en) Novel trypanosomal vaccine
MX390682B (es) Vacunas que contienen patogenos de cerdo para uso no mixto asociado.